Skip to content

Comparing the effects of Anethum graveolens and Mefenamic acid on the severity and duration of primary dysmenorrhea

Comparing the effects of Anethum graveolens and Mefenamic acid on the severity and duration of primary dysmenorrhea in students

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180707040370N15
Enrollment
117
Registered
2025-09-28
Start date
2025-11-21
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Dysmenorrhea. Primary Dysmenorrhea

Interventions

Intervention 1: Intervention group 1: 500 mg dill seed capsules will be used two days before menstruation and the first three days of menstruation, two capsules per day during two menstrual cycles.The

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 24 Years

Inclusion criteria

Inclusion criteria: Regular menstruation at intervals of 21-35 days No chronic diseases or diseases of the genital tract No history of ovarian cysts Insensitivity to herbal medicine No specific treatment to relieve dysmenorrhea symptoms in the past 3 months Being 18-24 years old

Exclusion criteria

Exclusion criteria: Intolerance and sensitivity to the medication being used Improper use of medications or discontinuation of use Taking any other herbal or chemical medicine during the intervention

Design outcomes

Primary

MeasureTime frame
Pain intensity. Timepoint: Before intervention, immediately after intervention and one month after intervention. Method of measurement: McGill Pain Scale to determine pain intensity, which ranges from zero, meaning no pain, to 10, meaning severe pain.;Duration of pain. Timepoint: Before intervention, immediately after intervention and one month after intervention. Method of measurement: The duration of pain before use, the first and second cycles after use are asked from the people participating in the study.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEnsiyeh Jenabi

Hamedan University of Medical Sciences

en.jenabi@yahoo.com+98 81 3838 0496

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026